The S&P Select Biotech Index remained above the 50-day moving average as investors look forward to this Wednesday's CPI data to refine expectations for rate cuts. The recent volatility spike has raised the stakes for economic data as the inevitable pivot point is approached.
SMID biotech EPS came to a close with clear signs of life for companies beating expectations. Should macro picture align with these positive micro updates there very well may be breakout potential for the sector for the first time in a while.
Corporate Updates & Earnings:
Amicus Therapeutics (FOLD) reported revenue ahead (+4.5%) and raised FY 2024 revenue growth guidance to 26-31% from 25-30%
Amphastar (AMPH) announced topline (+6.6%) and EPS (+21%) beats
Axsome Therapeutics (AXSM) announced in line revenue and expects top-line data from the Phase 3 ADVANCE-2 study of AXS-05 in AD agitation in the second half of the year
Intra-Cellular Therapeutics (ITCI) announced topline (+2.2) and EPS beats. FY 2024 Caplyta sales guidance raised to $650-680 million
Gilead Sciences (GILD) reported topline (+3.3%) and EPS ahead and raised the lower end of 2024 EPS guidance by $0.05
Coherus Biosciences (CHRS) reported topline (+5.8%) and EPS ahead of the street with lead drug Udenyca beating numbers
Revance Therapeutics (RVNC) announced in-line revenue and reiteres FY2024 guidance for >$280 million revenue and cash funding through breakeven in 2025
Eli Lily (LLY) reported topline (+12%) and EPS beats driven by flagship GLP1 franchise. FY 2024 guidance was raised by $3 billion
Sarepta Therapeutics (SRPT) reported light revenue (-6.8%) with EPS ahead and provided 2025 revenue guidance of $2.9-3.1 billion
BeiGene (BGNE) reported topline (+13%) and EPS beats driven by flagship BTK inhibitor Brukinsa ($637 million)
Novo Nordisk (NVO) announced a revenue miss driven by light performance of weight loss drug Wegovy, impacted by supply constraints. FY 2024 operating profit guidance was lowered by 200 bps
Harmony Biosciences (HRMY) announced in-line 2Q revenue and EPS ahead ($1.05 vs street $0.33). 2024 Revenue guidance was reiterated
Acadia Pharmaceuticals (ACAD) reported topline and EPS ahead of the street with closely watched Rett Syndrome drug Daybue coming in light (-5%). 2024 guidance was narrowed with Nuplazid estimates increasing and Daybue decreasing
Amgen (AMGN) announced in line revenue and a slight EPS miss. Focus remains on the upcoming Q4 obesity program update
Dynavax (DVAX) announced slight revenue miss with EPS ahead. 2024 Heplisav guidance was reiterated to $265-280 million
Madrigal Pharmaceuticals (MDGL) reported closely watched NASH therapy Rezdiffra revenue of $14.6 million.
Pacira Biosciences (PCRX) shares were under pressure after the U.S. District Court in NJ ruled the '495 patent was invalid. The company is considering an appeal
Comments